Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women infected with Schistosoma japonicum.

An estimated 40 million women of reproductive age are infected with one of three species of the waterborne parasite Schistosoma (S.) spp. Treatment with praziquantel (PZQ) via mass drug administration (MDA) campaigns is the mainstay of schistosomiasis control for populations living in endemic areas. The World Health Organization recommends that pregnant and lactating women be included in schistosomiasis MDA programs and several recent studies have evaluated the safety and efficacy of PZQ use during pregnancy. To date, there are no data describing PZQ pharmacokinetics (PK) during pregnancy or among lactating postpartum women. As part of a randomized controlled trial investigating the safety and efficacy of PZQ during human pregnancy, we examined the PK of this therapeutic drug among three distinct cohorts of women infected with S. japonicum in Leyte, The Philippines. Specifically, we studied the PK properties of PZQ among early and late gestation pregnant women (N= 15 each) and lactating post-partum women (N=15) with schistosomiasis. We found that women in early pregnancy had increased apparent clearance and lower Area-Under-the-Curve (AUC0-24) that may be related to physiological changes in drug clearance and/or changes in oral bioavailability. There was no relationship between body weight and apparent clearance. The mean ± standard deviation partition ratio of plasma to breast milk was 0.36. ± 0.13 . The estimated median infant PZQ daily dose would be 0.037 mg/kg ingested from breast milk, which is significantly lower than the dosage required for anti-schistosomal activity and not known to be harmful to the infant. Our PK data do not support suggestion to delay breastfeeding 72 hours after taking PZQ. Results can help inform future drug efficacy studies in pregnant and lactating women with schistosomiasis.